Pharmaceuticals News and Research

RSS

Ventana partners with Incyte to develop companion diagnostic tests for oncology drug programs

Ventana Medical Systems, Inc., a member of the Roche Group, today announced that it has entered into an agreement with Incyte Corporation to collaborate on the development of companion diagnostic tests for Incyte's oncology drug programs, beginning with the Incyte IDO1 inhibitor program.

5 Nov 2013

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2013 financial results.

5 Nov 2013

Community pharmacist program improves COPD care

Patients with chronic obstructive pulmonary disease who receive a community pharmacist-based intervention have improved inhalation technique and medication adherence, show the results of a randomized trial.

5 Nov 2013

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.

5 Nov 2013

Access to health care increases prescription opioid abuse

Researchers at Indiana University-Purdue University Indianapolis say one way to gauge the extent of prescription opioid pain reliever abuse in any Indiana county is to count the number of health care providers, particularly dentists and pharmacists.

5 Nov 2013

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Reviva Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the discovery and development of new, safer and highly effective therapies for chronic indications, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration for its lead, new investigational antipsychotic drug, RP5063.

5 Nov 2013

Janssen Pharmaceuticals to pay over $1.6 billion in drug misbranding case

On behalf of the U.S. Food and Drug Administration, the U.S. Department of Justice today announced a guilty plea agreement with Janssen Pharmaceuticals, Inc., of Titusville, N.J., and a $400 million criminal fine for introducing a misbranded drug, Risperdal (risperidone), into interstate commerce.

5 Nov 2013

Officials give drug companies the OK to help patients with costly drug co-pays in insurance exchanges

Federal officials last week OK'd allowing pharmaceutical companies to help cover patient out-of-pocket costs for costly drugs in the health law's insurance exchanges, a closely watched move by drug companies and patient advocates.

5 Nov 2013

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Biothera announced today top-line results from its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) that evaluated its immunotherapeutic drug candidate, Imprime PGG®, with cetuximab (Erbitux®), carboplatin and paclitaxel compared with the monoclonal antibody and chemotherapy combination alone.

5 Nov 2013

Avedro gets CE Mark clearance for KXL II System

Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company, announces CE Mark clearance for its KXL II System. The KXL II System has the potential for non-surgical correction of myopia, as well as improving cataract surgery outcomes, with a procedure called PiXL (Photorefractive Intrastromal Cross-linking).

5 Nov 2013

CHEO-led study confirms validity, reliability of quality of life measurement tool for thalassemia major

A CHEO-led multi-site North American study, headed by Dr. Robert Klaassen, lead investigator at CHEO and associate professor in the University of Ottawa's Department of Pediatrics, has confirmed the validity and reliability of a quality of life measurement tool for children and adults with thalassemia major.

5 Nov 2013

Stem cell therapy after traumatic brain injury promotes lasting cognitive improvement

A stem cell therapy previously shown to reduce inflammation in the critical time window after traumatic brain injury also promotes lasting cognitive improvement, according to preclinical research led by Charles Cox, M.D., at The University of Texas Health Science Center at Houston (UTHealth) Medical School.

4 Nov 2013

Nanomedicine Award winners officially announced at BIO-Europe conference

The winners of the first ever Nanomedicine Award were officially announced during the Nanomedicine Panel at BIO-Europe conference in Vienna, November 4th 2013. The Award review Board agreed to distinguish two projects in two different categories: The winners are Endomagnetics Ltd in the nanodiagnostic category and the I-CARE project from Linköping University in the regenerative medicine category.

4 Nov 2013

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

BioLineRx, a biopharmaceutical development company, announced today that it has received regulatory approval from the Finnish National Supervisory Authority for Welfare and Health (Valvira) to commence a Phase 1/2 safety trial for BL-7010, for the treatment of celiac disease.

4 Nov 2013

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.

4 Nov 2013

First Edition: November 4, 2013

Today's headlines include the latest on the efforts to address the problems with healthcare.gov, as well as the continuing controversy surrounding President Barack Obama's promise that Americans could keep their health coverage if they liked it juxtaposed with the news of recent policy cancellations.

4 Nov 2013

Boehringer Ingelheim's Phase II trial of interferon-free hepatitis C treatment shows promising results

Interim data presented today show that all patients (13/13) who reached their 4-week post-treatment follow-up have undetectable levels of hepatitis C virus (SVR4) after completing a 12-week regimen of faldaprevir, deleobuvir, PPI-668 and ribavirin.

4 Nov 2013

Polyphor, Roche agree to develop and commercialize antibiotic for bacterial infections

Polyphor Ltd, a privately held pharmaceutical company, and Roche announced today that they have entered into an exclusive worldwide license agreement to develop and commercialize Polyphor's investigational macrocycle antibiotic, POL7080, for patients suffering from bacterial infections caused by Pseudomonas aeruginosa.

4 Nov 2013

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, announced that its most advanced ImmTAC drug, IMCgp100 for the treatment of late stage melanoma, has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed. The company has now initiated a Phase IIa clinical trial in the UK and USA.

1 Nov 2013

Oncology drug development services: an interview with Dr. Jean-Pierre Wery, President of Crown Bioscience, Inc.

Crown serves pharmaceutical companies and biotech companies. We have two areas of focus: oncology and metabolic diseases. In the oncology space we focus on pre-clinical services. Essentially, we have all the tools to help our customers move from target discovery, target validation, to a clinical candidate.

31 Oct 2013

Pharmaceuticals News and Research

Ventana partners with Incyte to develop companion diagnostic tests for oncology drug programs

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Community pharmacist program improves COPD care

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Access to health care increases prescription opioid abuse

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Janssen Pharmaceuticals to pay over $1.6 billion in drug misbranding case

Officials give drug companies the OK to help patients with costly drug co-pays in insurance exchanges

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Avedro gets CE Mark clearance for KXL II System

CHEO-led study confirms validity, reliability of quality of life measurement tool for thalassemia major

Stem cell therapy after traumatic brain injury promotes lasting cognitive improvement

Nanomedicine Award winners officially announced at BIO-Europe conference

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

First Edition: November 4, 2013

Boehringer Ingelheim's Phase II trial of interferon-free hepatitis C treatment shows promising results

Polyphor, Roche agree to develop and commercialize antibiotic for bacterial infections

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Oncology drug development services: an interview with Dr. Jean-Pierre Wery, President of Crown Bioscience, Inc.

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence